Is PLRX or PLX more undervalued in 2026?

CirclFi compares Pliant Therapeutics, Inc. (PLRX) and Protalix BioTherapeutics, Inc. (PLX) using 13 institutional-grade valuation models. PLRX has a Quality of Company score of 4.3/10 while PLX scores 7.6/10.

Which is a better buy — PLRX or PLX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLRX and PLX valuations compare?

PLRX at $1.25 and PLX at $2.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLRX vs PLX Valuation Comparison 2026 — Intrinsic Value Analysis

PLRX

Biotechnology

Pliant Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$1.25

Last close

Models

7/13

Active

PLX

Biotechnology

Protalix BioTherapeutics, Inc.

Quality

7.6

out of 10

Value Trap

SAFE

Price

$2.10

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	PLRX Fair Value	PLRX Upside	PLX Fair Value	PLX Upside
Bayesian DCF	Intrinsic	$0.12	-90.6%	$1.66	-20.9%
Earnings Power Value	Intrinsic	—	—	$3.20	+52.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.22	+157.7%	$0.50	-76.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLRX vs PLX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLRX vs PLX — Which Stock Is More Undervalued?

PLX scores higher with a 7.6/10 quality rating vs PLRX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pliant Therapeutics, Inc. (PLRX) and Protalix BioTherapeutics, Inc. (PLX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLRX currently trades at $1.25 with a QOC of 4.3/10, while PLX trades at $2.10 with a QOC of 7.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).